Moomoo AI 已提取核心信息
Panbela Therapeutics, Inc. has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, with the file number 333-276367. The request, dated January 25, 2024, was made under Rule 461 of the Securities Act of 1933, as amended. The company seeks to have the Registration Statement become effective on the same day at 5:30 p.m. Eastern Time, or as soon thereafter as possible. This step is in preparation for a proposed public offering of securities by Panbela Therapeutics. The company has acknowledged its responsibilities under the Act in relation to the offering. Any inquiries regarding this acceleration request have been directed to Joshua L. Colburn of Faegre Drinker Biddle & Reath LLP, who is serving as counsel for Panbela Therapeutics. The communication was signed by Susan Horvath, the Chief Financial Officer of Panbela Therapeutics.
Panbela Therapeutics, Inc. has formally requested the United States Securities and Exchange Commission (SEC) to accelerate the effective date of its Registration Statement on Form S-1, with the file number 333-276367. The request, dated January 25, 2024, was made under Rule 461 of the Securities Act of 1933, as amended. The company seeks to have the Registration Statement become effective on the same day at 5:30 p.m. Eastern Time, or as soon thereafter as possible. This step is in preparation for a proposed public offering of securities by Panbela Therapeutics. The company has acknowledged its responsibilities under the Act in relation to the offering. Any inquiries regarding this acceleration request have been directed to Joshua L. Colburn of Faegre Drinker Biddle & Reath LLP, who is serving as counsel for Panbela Therapeutics. The communication was signed by Susan Horvath, the Chief Financial Officer of Panbela Therapeutics.
Panbela Therapeutics, Inc.已正式要求美国证券交易委员会（SEC）加快其文件编号为333-276367的S-1表格注册声明的生效日期。该请求的日期为2024年1月25日，是根据经修订的1933年《证券法》第461条提出的。该公司力求使注册声明在东部时间当天下午 5:30 生效，或在此之后尽快生效。这一举措是为Panbela Therapeutics拟议的公开发行证券做准备。该公司已承认其根据该法案承担的与发行有关的责任。有关该加速请求的任何询问均已转交给担任Panbela Therapeutics法律顾问的Faegre Drinker Biddle & Reath LLP的约书亚·科尔本。该信函由Panbela Therapeutics首席财务官苏珊·霍瓦斯签署。
Panbela Therapeutics, Inc.已正式要求美国证券交易委员会（SEC）加快其文件编号为333-276367的S-1表格注册声明的生效日期。该请求的日期为2024年1月25日，是根据经修订的1933年《证券法》第461条提出的。该公司力求使注册声明在东部时间当天下午 5:30 生效，或在此之后尽快生效。这一举措是为Panbela Therapeutics拟议的公开发行证券做准备。该公司已承认其根据该法案承担的与发行有关的责任。有关该加速请求的任何询问均已转交给担任Panbela Therapeutics法律顾问的Faegre Drinker Biddle & Reath LLP的约书亚·科尔本。该信函由Panbela Therapeutics首席财务官苏珊·霍瓦斯签署。
有用
没用
该公告为独立文件：
